UK Biobank Pharma Proteomics Project Support
Population-scale biomarker discovery across multiple diseases
Key Facts
About Olink Proteomics
Olink Proteomics, founded in 2004 and acquired by Thermo Fisher Scientific, is a leader in next-generation proteomics. The company's proprietary Proximity Extension Assay (PEA) technology uniquely combines antibody-based protein detection with DNA amplification, allowing for highly specific, scalable, and sensitive multiplex protein measurement. Its platform is widely used in large-scale population studies (e.g., UK Biobank) and pharmaceutical R&D for biomarker discovery and validation across various therapeutic areas, including neurodegeneration. Olink operates as a platform and services business, generating revenue from assay kits, panels, and associated bioinformatics software.
View full company profile